TY - JOUR
T1 - Relapsed Synovial Sarcoma
T2 - Treatment Options
AU - Weiss, Mia C.
AU - Van Tine, Brian A.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/3
Y1 - 2023/3
N2 - Synovial sarcoma (SS) is a fusion-driven subtype of sarcoma that is a more chemo-sensitive subtype of soft tissue sarcoma. While chemotherapy options are currently standard of care, our fundamental understanding of the biology of SS is driving new therapies. We will review the current standard of care, as well as the current therapies showing promise in a clinical trial. It is our hope that by encouraging participation in clinical trials, the fundamental therapies available for SS will change the current treatment paradigm.
AB - Synovial sarcoma (SS) is a fusion-driven subtype of sarcoma that is a more chemo-sensitive subtype of soft tissue sarcoma. While chemotherapy options are currently standard of care, our fundamental understanding of the biology of SS is driving new therapies. We will review the current standard of care, as well as the current therapies showing promise in a clinical trial. It is our hope that by encouraging participation in clinical trials, the fundamental therapies available for SS will change the current treatment paradigm.
UR - http://www.scopus.com/inward/record.url?scp=85149768180&partnerID=8YFLogxK
U2 - 10.1007/s11864-023-01056-5
DO - 10.1007/s11864-023-01056-5
M3 - Article
C2 - 36867389
AN - SCOPUS:85149768180
SN - 1527-2729
VL - 24
SP - 229
EP - 239
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 3
ER -